D J Kempf

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

A. D. Rodrigues, J. Leonard, A. Hsu, 1997, Antimicrobial agents and chemotherapy.

Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.

L. Everitt, A. Kaplan, D. Norbeck, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor

D. Ho, T. Bhat, M. Markowitz, 1995, Journal of virology.

A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.

K D Stewart, A Molla, D J Kempf, 1996, Journal of medicinal chemistry.

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

D Norbeck, D. Ho, D. Norbeck, 1994, Journal of virology.

Structure-based, C2 symmetric inhibitors of HIV protease.

S. Vasavanonda, D. Norbeck, D. Kempf, 1990, Journal of medicinal chemistry.

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

S. Vasavanonda, D. Norbeck, D. Kempf, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Ritonavir and saquinavir combination therapy for the treatment of HIV infection.

R Rode, M Salgo, D. Ho, 1999, AIDS.

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.

D. Norbeck, D. Kempf, J. Erickson, 1990, Science.